GCM can potentiate liver cancer cells to ABT-737-induced apoptosis in both cell culture and animal models by targeting TOPK-survivin pro-survival signaling pathway and inhibiting ACC-mediated de novo lipogenesis (Figure 7). The gene discussed is BIRC5; the disease is liver cancer.